Traditional Chinese Medicine Augmentation Therapy for Obsessive-Compulsive Disorder (TCMA-OCD)
Study of Traditional Chinese Medicine Augmentation Therapy for Obsessive-Compulsive Disorder With Nonresponse to Initial Treatment
Obsessive-compulsive disorder (OCD) is a psychiatric disorder characterized by recurrent intrusive obsessive thoughts, urges, and ritualized compulsive behaviors. OCD often follows a chronic and protracted course with a high risk of relapse and is frequently accompanied by comorbid anxiety, depression, and other negative emotional symptoms, resulting in substantial impairment in occupational functioning, interpersonal relationships, and family and social functioning.Integrative treatment combining traditional Chinese medicine (TCM) and Western medicine may help address several limitations of conventional monotherapy, including suboptimal treatment response rates, medication-related adverse effects, the limited diversity of available therapeutic approaches, and insufficiently individualized treatment strategies, thereby offering potential clinical benefits.Chaixia Dingzhi Powder, the investigational Chinese herbal formula used in this study, was developed based on the formulation principles of two classical TCM prescriptions, Xiaoyao San (Free and Easy Wanderer Powder), documented in the Taiping Huimin Heji Jufang (Formulary of the Pharmacy Service for Benefiting the People in the Taiping Era), and Banxia Houpo Tang (Pinellia and Magnolia Bark Decoction), recorded in the Jingui Yaolue (Essentials from the Golden Cabinet). The formula was further modified according to the TCM pathophysiological characteristics of the target population, particularly liver qi stagnation with spleen deficiency, impaired qi movement, and the interaction of phlegm and qi stagnation.Therefore, this study aims to further investigate the efficacy and safety of Chaixia Dingzhi Powder as an adjunctive traditional Chinese medicine (TCM) treatment in patients with obsessive-compulsive disorder (OCD) who have demonstrated nonresponse to initial SSRI treatment, while maintaining their existing SSRI therapy at an adequate therapeutic dose or the maximum tolerated dose.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ2
- フェーズ 1
連絡先と場所
研究連絡先
研究連絡先
- 名前:Lanying LIU
- 電話番号:13516816012
- メール:balindaliu@126.com
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
1)Aged 16-65 years; 2)Meet the diagnostic criteria for obsessive-compulsive disorder (OCD) according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5); 3)Have received continuous SSRI monotherapy at the maximum recommended dose or maximum tolerated dose for at least 8 consecutive weeks; 4)Have a Yale-Brown Obsessive Compulsive Scale (Y-BOCS) total score >12 or a Clinical Global Impression-Severity (CGI-S) score ≥3; 5)Meet the traditional Chinese medicine (TCM) syndrome differentiation criteria for liver qi stagnation and spleen deficiency.
Exclusion Criteria:
1)Meet the DSM-5 diagnostic criteria for any psychiatric disorder other than obsessive-compulsive disorder (OCD), with the exception of obsessive-compulsive personality disorder (OCPD); 2)Meet the criteria for treatment-resistant obsessive-compulsive disorder (TR-OCD) as defined in the Chinese Guidelines for the Prevention and Treatment of Obsessive-Compulsive Disorder; 3) Meet the traditional Chinese medicine (TCM) syndrome differentiation criteria for any syndrome other than liver qi stagnation and spleen deficiency; 4)Women who are pregnant, planning to become pregnant in the near future, or breastfeeding; 5)Have a history of substance abuse within the past 12 months; 6) Have a history of severe drug allergies; 7)Have any other condition that, in the investigator's judgment, makes them unsuitable for participation in the study.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
プラセボコンパレーター:Control Group
Placebo Group |
Participants will receive Chai-Xia Ding-Zhi Powder placebo as an adjunctive treatment for 8 weeks while continuing SSRIs at their original dosage. |
|
実験的:Intervention Group
Chai-Xia Ding-Zhi Powder Group |
Participants will receive Chai-Xia Ding-Zhi Powder as an adjunctive treatment for 8 weeks while continuing SSRIs at their original dosage. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
Y-BOCS Score
時間枠:8 weeks
|
8 weeks
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- 2026-92
- ZDYN-2024-A-013 (その他の助成金/資金番号:National Administration of Traditional Chinese Medicine (NATCM))
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。